Novartis AG (NVSEF)
102.14
+1.52
(+1.51%)
USD |
OTCM |
May 17, 16:00
Novartis Enterprise Value: 224.32B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 224.32B |
| May 16, 2024 | 221.22B |
| May 15, 2024 | 221.22B |
| May 14, 2024 | 224.04B |
| May 13, 2024 | 224.04B |
| May 10, 2024 | 224.02B |
| May 09, 2024 | 213.18B |
| May 08, 2024 | 219.02B |
| May 07, 2024 | 212.35B |
| May 06, 2024 | 210.22B |
| May 03, 2024 | 209.23B |
| May 02, 2024 | 213.84B |
| May 01, 2024 | 213.84B |
| April 30, 2024 | 213.84B |
| April 29, 2024 | 211.80B |
| April 26, 2024 | 211.80B |
| April 25, 2024 | 211.80B |
| April 24, 2024 | 211.80B |
| April 23, 2024 | 211.80B |
| April 22, 2024 | 209.98B |
| April 19, 2024 | 200.04B |
| April 18, 2024 | 200.04B |
| April 17, 2024 | 206.98B |
| April 16, 2024 | 206.98B |
| April 15, 2024 | 206.98B |
| Date | Value |
|---|---|
| April 12, 2024 | 206.98B |
| April 11, 2024 | 206.98B |
| April 10, 2024 | 207.92B |
| April 09, 2024 | 211.18B |
| April 08, 2024 | 209.57B |
| April 05, 2024 | 209.57B |
| April 04, 2024 | 209.57B |
| April 03, 2024 | 204.53B |
| April 02, 2024 | 209.76B |
| April 01, 2024 | 212.84B |
| March 31, 2024 | 212.84B |
| March 28, 2024 | 207.91B |
| March 27, 2024 | 206.21B |
| March 26, 2024 | 206.21B |
| March 25, 2024 | 206.21B |
| March 22, 2024 | 207.67B |
| March 21, 2024 | 207.67B |
| March 20, 2024 | 202.90B |
| March 19, 2024 | 208.71B |
| March 18, 2024 | 215.04B |
| March 15, 2024 | 215.04B |
| March 14, 2024 | 215.04B |
| March 13, 2024 | 211.16B |
| March 12, 2024 | 211.61B |
| March 11, 2024 | 212.48B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
138.96B
Minimum
Oct 13 2022
233.44B
Maximum
Jan 23 2024
186.07B
Average
188.93B
Median
Enterprise Value Benchmarks
| Sandoz Group AG | -- |
| Roche Holding AG | 236.22B |
| ADC Therapeutics SA | 273.48M |
| AC Immune SA | 198.33M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.688B |
| Revenue (Quarterly) | 12.12B |
| Total Expenses (Quarterly) | 8.747B |
| EPS Diluted (Quarterly) | 1.31 |
| Gross Profit Margin (Quarterly) | 74.46% |
| Profit Margin (Quarterly) | 22.18% |
| Earnings Yield | 7.18% |
| Operating Earnings Yield | 5.02% |
| Normalized Earnings Yield | 4.327 |